# Epinephrine Dose: Optimal Versus Standard Evaluation Trial

Study · id `cardio:ct-nct03826524` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03826524](<https://clinicaltrials.gov/study/NCT03826524>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03826524

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1250 participants.

## Technical summary

Registry record NCT03826524. Randomized; triple masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1250 participants (planned count; ClinicalTrials.gov record NCT03826524, source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)
- Started: 2023-05-24 (actual) (ClinicalTrials.gov record NCT03826524, source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT03826524, source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT03826524, source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03826524, source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03826524-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Epinephrine Dose: Optimal Versus Standard Evaluation Trial
- Acronym: EpiDOSE
- Condition: Cardiac Arrest, Out-Of-Hospital
- Condition: Sudden Cardiac Arrest
- Condition: Ventricular Fibrillation
- Condition: Ventricular Tachycardia-Pulseless
- Intervention (Drug): Epinephrine
- Lead sponsor: Unity Health Toronto
- Lead sponsor class: OTHER
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)
- Registry lists this organization as the lead sponsor: Unity Health Toronto (`cardio:org-unity-health-toronto`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

## Provenance

Content hash: ae2d73f6be7b52faf448b4975ed054e7d5008bd7283690fc0f92a3ff679d7b86
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
